Contineum Therapeutics, Inc.
CTNM
$4.76
$1.1130.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.13% | 30.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.24% | 31.39% | |||
| Operating Income | -6.24% | -31.39% | |||
| Income Before Tax | -9.78% | -41.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.78% | -41.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.78% | -41.86% | |||
| EBIT | -6.24% | -31.39% | |||
| EBITDA | -6.25% | -31.44% | |||
| EPS Basic | -9.55% | -41.40% | |||
| Normalized Basic EPS | -9.56% | -41.38% | |||
| EPS Diluted | -9.55% | -41.05% | |||
| Normalized Diluted EPS | -9.56% | -41.38% | |||
| Average Basic Shares Outstanding | 0.21% | 0.33% | |||
| Average Diluted Shares Outstanding | 0.21% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||